Abstract. Oncolytic adenoviruses are modified based on adenovirus serotype 5 (Ad5), which belongs to subgroup C and depends on Coxsackie-adenovirus receptor (CAR) to recognize target cells. However, expression of CAR is generally low or lost in certain tumors including hepatocellular carcinoma (HCC). By contrast, CD46 is highly expressed in various types of malignant tumor cells. Therefore, we constructed an adenovirus vector expressing the human RANTES/CCL5 gene regulated by oxygen-dependent degradation domain (ODD) and analyzed its antitumor effects in vitro and in vivo. The human RANTES/CCL5 gene was fused with ODD by PCR and the recombinant oncolytic adenovirus containing RANTES-ODD, SG511-CCL5-ODD, was constructed by the Gateway system, which infected cells by binding CD46. Viral replication experiments were performed to evaluate the selective replication ability of SG511-CCL5-ODD. RANTES expression was determined by ELISA. The chemotactic test was used to analyze the ability of the expressed RANTES to recruit NK92 cells. The antitumor effects of SG511-CCL5-ODD were examined in HCC xenografts in nude mice. A chimeric oncolytic adenovirus, SG511-CCL5-ODD highly expressed the RANTES-ODD fusion gene in the hypoxia of HCC under the control of the ODD and effectively attracted NK92 cells and a high number of immunocytes. These factors had complementary advantages and, in combination, exerted enhanced antitumor efficacy.

Introduction

T cells provoke the antitumor immune response; therefore, T cell-mediated immunotherapy is regarded as a crucial approach in cancer treatment. The adoptive cell transfer (ACT) combined with lymphodepletion has led to clinical tumor suppression in 50-70% of patients with metastatic melanoma (1). However, the large number of activated and expanded T cells required in the laboratory (more than 1x10^9) makes ACT a costly and labor-intensive treatment (2-4).

Owing to the marked effects in the treatment of metastatic melanoma and the evident impact on cancer regression in approximately 50% of patients, development of ACT therapy utilizing autologous tumor-infiltrating lymphocytes (TIL) is gaining momentum (5,6). In addition, although some ACT-treated patients achieved long-term survival, the majority experienced cancer relapse (7). Therefore, strategies aimed at improving the migration of T cells into tumor sites are likely to enhance the efficacy of ACT therapy.

Immune cells trafficking to inflammation sites are usually affected by chemokines. Through chemotaxis, cells that express appropriate chemokine receptors can migrate along with a chemokine gradient to specific tissues or infection sites (8). Chemokines also play an important role in T cell-mediated anti-tumor immune responses (9-11). A variety of immunocytes have strong chemotactic effects after being regulated upon the activation of normal T-cell expressed and secreted RANTES/CCL5 that chemotactically attracts a huge number of immunocytes to tumor tissues to exert antitumor efficacy (12-17).

As a result of immune response unable to eradicate tumor cells, cancer develops. There may be mechanisms significantly involved in tumor development, which allow tumor cells to escape immune surveillance from natural killer (NK) and other
Immune cells (18-20). NK cells represent distinct subsets of lymphoid cells with innate immune functions (21). NK cells are derived from the bone marrow, they circulate in the blood and then become activated by cytokines or upon encountering target cells expressing ligands for NK cell receptors (22). NK cells provide one of the first lines of defense against virus-infected and tumor cells. In general, no immune receptor gene rearrangement occurs in them and their cytotoxicity is not MHC-restricted. NK cells are able to mediate the spontaneous killing of various tumor cells without prior sensitization. To date, not all NK cell lines can be established from patients with large granular lymphoma (23) and, with regard to the in vitro tumoricidal properties, these NK cell lines show considerable differences, although some of them have been shown to maintain cytotoxicity (23,24).

Isolated from peripheral lymphocytes of a non-Hodgkin's lymphoma patient in 1992 (25), NK-92 was successfully set up as a natural anti-IL-2 dependent cell line, with similar functional characteristics as human NK cells. Research demonstrated that NK-92 cells showed high cytotoxic activity against tumor cell lines from leukemia (26) and malignant melanoma (27). Additionally, in vivo application of NK-92 was tested in immune deficiency (SCID) mouse models, xenografted with patient-derived leukemia (T-ALL, AML) (24) or human malignant melanoma cell lines (27). Tumor burden was reduced or undetectable and the survival of mice was significantly improved. NK-92 cells are constantly being developed for adoptive immunotherapy in cancer treatment and have entered clinical trials (28).

The most widely-used oncolytic adenoviruses in cancer therapy are based on adenovirus serotype 5 (Ad5), which belongs to subgroup C and Coxsackie adenovirus receptor (CAR) on target cells are necessary for successful transduction (29,30). However, expression of CAR is generally low or lost in the process of the malignant progression of certain tumors, including hepatocellular carcinoma (HCC) (31-33), limiting the transduction of Ad5-based vectors in some tumor cells and resulting in impaired antitumor effects (31). By contrast, CD46, a cellular receptor for Ad11 (subgroup B) (34), is highly expressed in various types of malignant tumor cells including HCC (35-38). Therefore, to address the issue of CAR-dependent cell entry, novel fiber chimeric adenoviral vectors have recently been designed by switching the knob and shaft of the Ad5 fiber to those of the Ad11 fiber that can recognize the abundant CD46 receptor on tumor cells (39). Previous studies have indicated that viral entry and antitumor activity could be greatly improved by 5/11 fiber chimeric oncolytic adenoviruses compared with Ad5-based viruses (40,41). Nevertheless, the tumor-suppressing capacity of 5/11 fiber chimeric oncolytic adenoviruses in HCC have yet to be fully explored.

Genetic modification of signal pathways promoting cell growth and survival leads to the emergence of tumor cells, whose expansion depends on nutrient supply. Oxygen limitation is crucial for controlling angiogenesis, glucose metabolism, survival and tumor spread. This effect is orchestrated by hypoxia-inducible factor (HIF), a main transcriptional factor in nutrient stress signal. Variations in oxygen tension (pO2) are not directly sensed by HIF but by a class of 2-oxoglutarate-dependent and iron-dependent dioxygenases which belong to the family of non-haem oxidizing enzymes. Due to strict control of pO2 to the activity, these enzymes are the true oxygen-sensing molecules controlling the hypoxic response. Two types of oxygen sensors control HIF action; the first are known as the prolyl hydroxylase domain (PHD) proteins. PHDs hydroxylate two prolyl residues (P402 and/or P564) in the human HIF-1α region considered the oxygen-dependent degradation domain (ODD). This HIF-α modification specifies rapid interaction with the tumor-suppressor protein von Hippel-Lindau (VHL), a component of an E3 ubiquitin ligase complex. As a result, HIF-α subunits are marked with polyubiquitin chains driving them to destruction by the proteasomal system. ODD is closely related to the rapid degradation of intracellular proteins (42). Some proteins with ODD display instability under normoxia, but stability under hypoxia. Hypoxia exists within most solid tumors (43-46). Hence, as a regulatory element, the translated ODD can lead to a concentration of certain proteins at a specific high level.

Therefore, we constructed a chimeric adenovirus SG511-CCL5-ODD carrying RANTES-ODD fusion gene. We hypothesized that in hypoxia of HCC, RANTES is highly expressed under the control of ODD and attracts a large number of immunocytes to tumor tissues to exert antitumor efficacy. NK92 cells were also administered by tail vein injection and they can be attracted to the tumor site by RANTES. In the HCC tumor site, SG511-CCL5-ODD and NK92 cells jointly exerted an enhanced antitumor activity.

Materials and methods

Cell lines and culture. Human primary HCC cell lines Hep3B and SK-Hep-1 and human normal fibroblast cell lines BJ were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). Human HCC cell lines, SMMC-7721, BEL-7404 and BEL-7405 and human normal hepatocellular cell lines L02 were obtained from the Institutes of Cell Biology, Chinese Academy of Sciences (Shanghai, China). The human embryonic kidney (HEK) 293 cell line was obtained from Microbix Biosystem, Inc. (Toronto, ON, Canada). NK-92 was purchased from the American Type Culture Collection, and was maintained in α medium (Gibco BRL, Gaithersburg, MD, USA) supplemented with 2 mM L-glutamine, 0.2 mM i-inositol, 20 mM folic acid, 0.1 mM 2-mercaptoethanol, 12.5% fetal bovine serum (FBS) and 12.5% horse serum containing 100 U human IL-2 (Sigma). L02, SMMC-7721, BEL-7404 and BEL-7405 were maintained in RPMI-1640 with 10% FBS and HEP293, SK-Hep-1 and Hep3B were maintained in Dulbecco's modified Eagle's medium (Gibco BRL) in a 5% CO2 atmosphere at 37°C, containing 10% FBS. BJ was maintained in modified Eagle's medium (Gibco BRL) in a 5% CO2 atmosphere at 37°C, containing 10% FBS. All media were supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin. Hypoxic conditions (1% O2) were achieved with a three-gas incubator (Thermo Scientific).

Construction of adenovirus. pCMV-SPORT6 vector containing human RANTES gene was purchased from Proteintech Group, Inc. Ad5/F11 mosaic adenovirus plasmids, pPE3-F11-ccdB, pSG500 (47), pPE3-F11, were modified in our lab. pPE3-F11 was constructed by switching the knob and shaft of the
ONCOLOGY REPORTS 29: 895-902, 2013

P. DOUGLAS AND M. LOIDE

According to the kit protocol, and the spectrophotometrical absorption of the samples was read on a microtiter plate reader at 570 nm in a reference wavelength of 650 nm. The percentage of cell survival was calculated using the formula: Cell survival (%) = (A value of infected cells/A value of uninfected control cell) x 100%. Eight replicating samples were obtained at each MOI and each experiment was performed at least three times.

Transwell chamber chemotactic assay. Serum-free MEM/αM (containing 2x10^5 cell/200 µl) was added to the upper compartment of the invasion chamber. Conditioned medium (1 ml) was added to the lower compartment of the invasion chamber. The lower compartment of the invasion chamber of the control and the standard group were supplemented with 1 ml serum-free MEM/αM and 1 ml containing 1 ng/ml RANTES serum-free MEM/αM, respectively. The invasion chambers were incubated at 37°C for 24 h, and the inserts and cells on the upper side of the filter were then removed. Cells that invaded the underside of the filter were counted. Each experiment was repeated three times. The values obtained were calculated by averaging the total number of cells from triplicate determinations.

Animal experiments. BALB/c nude mice (nu/nu) were purchased from the Shanghai Experimental Animal Center, Chinese Academy of Sciences. SMMC-7721 cancer cells in log phase were subcutaneously injected into the right flanks of mice (1x10^6 per mouse). Two weeks later, the tumor xenografts were established, 40 mice were randomly assigned to four groups (SG511, AD5/11-CCL5-ODD, SG511-CCL5-ODD and the control group, n=10 mice/group). Tumors were then injected with 100 µl control buffer or 2x10^6 pfu of viruses. The injections were repeated every other day for five times, with a total dosage of 1x10^9 pfu.

Other SMMC-7721 tumor xenograft models were established as mentioned above to evaluate the combined antitumor efficacy of SG511-CCL5-ODD and NK-92. The mice were divided randomly into four groups: I (SG511-CCL5-ODD), II (NK-92), III (SG511-CCL5-ODD+NK-92) and control (10 mice/group). Group I was given a total of 1x10^6 pfu viruses five times at intratumoral injection, once every other day. The mice in group II received intravenous inoculations of 2.5x10^7 NK-92 cells five times, once every other day. Group III received intratumoral injection of 2x10^6 pfu viruses in 100 µl viral preservation solution and at the indicated time after injection, 5x10^6 NK-92 in 200 µl of PBS were administered by intravenous inoculation, the animals received a series of five doses of viruses and NK-92 cells. In the control group, 100 µl viral preservation solution [10 mM Tris-HCl (pH 8.0), 2 mM MgCl₂, 4% sucrose] per mouse per time was injected intratumorally. Tumor volume was estimated with the formula: (maximal diameter) x (perpendicular diameter)^2 x 0.5. All animal experiments were performed according to the Guidelines for the Institutional Animal Care and Use Committee of The Second Military University (Shanghai, China).

Immunohistochemistry. Tumor samples were formalin-fixed and paraffin-embedded and successive sections for H&E staining and immunohistochemistry were prepared. CCL5-expressing cells were assayed by staining with a goat anti-human CCL5 (R&D) followed by incubation with a biotin-conjugated rabbit
anti-goat IgG and a horseradish peroxidase (HRP)-conjugated streptavidin (Southern Biotech). NK-92 cells were assessed by staining with a mouse anti-human CD56 (Santa Cruz) followed by incubation with a biotin-conjugated goat anti-mouse IgG and a horseradish peroxidase-conjugated streptavidin. The positive reaction was visualized with 3',3'-diaminobenzidine. The sections were examined by two independent investigators for qualitative and semiquantitative analysis.

Statistical analysis. Experiments were performed three times and data are shown as the means ± SD. Student’s t-test was used to interpret the significance of differences between every two groups. ANOVA for repeated measurement experiments was conducted to compare the tumor growth over time between the treated groups and the control group in the animal experiment. P<0.05 was considered to indicate statistically significant differences.

Results

Adenovirus selectively proliferates and mediates RANTES expression in HCC cells. The Ad5/F11 adenovirus showed a geometrical multiple proliferation in liver cancer cell lines, particularly in BEL-7404 with the proliferation multiple of 250,000 times in hypoxia at 96 h, demonstrating the virus has strong proliferation ability in cancer cells (Fig. 1A). The proliferation multiple of SG511-CCL5-ODD in the normal cell line was very low, showing that SG511-CCL5-ODD has weak proliferation ability in normal cells (Fig. 1B).

With the viral proliferation, Ad5/F11 chimeric adenoviruses express RANTES protein at high levels in SMMC-7721, BEL-7404 and BEL-7405 cells, reaching up to 35427.3 pg/ml in BEL-7404 cells in hypoxic conditions. Protein expression of the RANTES gene in hypoxia was much higher than that in normoxia in hepatoma cell lines; ODD can effectively regulate RANTES protein expression (Fig. 1C, P<0.05).

Cytotoxic specificity of SG511-CCL5-ODD by MTT assay. MTT assay was performed to characterize the specificity of SG511-CCL5-ODD in tumor cells. As shown in Fig. 2, SG511-CCL5-ODD caused significant cytolysis in the Hep3B, Sk-Hep-1 and SMMC-7721 cell lines at a MOI of 0.1 pfu/cell, 0.5 pfu/cell and 1 pfu/cell, respectively. However, normal cells infected with SG511-CCL5-ODD showed a >50% cell viability at an MOI of 10 pfu/cell, suggesting that >10-100-fold of SG511-CCL5-ODD were needed to kill half of the normal fibroblast cells compared with liver cancer cells (Fig. 2).
Transwell chamber chemotactic assay. The chemokine experimental results showed that, compared with the control group and the standard group which contained RANTES protein at 1 ng/ml in the lower compartment of the invasion chamber, the RANTES expressed by Ad5/F11 chimeric adenovirus presented the chemotactic activity for NK-92 cells. In hypoxia, the chemotactic effect was higher than in normal oxygen conditions (P<0.05) (Fig. 3).

Ad5/F11 chimeric adenovirus-mediated RANTES expression exerts antitumor potency in HCC xenograft models. In the SMMC-7721 xenograft models, SG511-CCL5-ODD intratumor treatment significantly inhibited tumor growth compared with the control group from day 14 post-treatment (P<0.001). Both SG511-CCL5-ODD and Ad5/11-CCL5-ODD treatment groups showed stronger antitumor activity than the SG511 group from day 14 post-treatment (P<0.05) (upper panel, Fig. 4). Mice were sacrificed after the observation period. Tumors were collected and examined pathologically by H&E staining (Fig. 4A-D).

Antitumor efficacy of SG511-CCL5-ODD combined with NK-92. The antitumor efficacy of SG511-CCL5-ODD combined with NK-92 was evaluated on SMMC-7721 tumor xenografts established in nude mice. Significant reduction of tumor volume was observed in all the treatment groups, with tumor inhibition rates of 51.19, 53.28 and 34%, respectively, for Group I (SG511-CCL5-ODD), Group II (NK-92), Group III (SG511-CCL5-ODD+NK-92), when compared with the control group (P<0.05) on day 14 after treatment, and 46.15, 46.42 and 32.7% on day 21, 61.04, 46.81 and 31.46% on day 28, respectively (Fig. 5A).

Mice were sacrificed 28 days later by cervical dislocation. All tumor samples were examined histologically using H&E staining (Fig. 5B) and immunohistochemical staining for RANTES (Fig. 5C). In the control group, cancer cells grew abundantly with small foci of necrosis. In the groups treated with replicating viruses or (and) NK-92 cells, several wide areas of necrosis were observed. There were many necrotic foci in tumor tissues of the SG511-CCL5-ODD combined NK-92 groups. Around the necrotic areas, most cancer cells were positive for RANTES expression, but there were no cancer cells positive for RANTES in the NK-92 and control groups.

Discussion

RANTES (CCL5) is an 8-kDa cytokine, with clear chemotactic activity to the cells which are involved in the immune/inflammatory response, such as lymphocytes, monocytes/macrophages. RANTES can also regulate the function of effector cells. Chemotaxis of RANTES relies on the concentration of RANTES. Therefore, the aggregation of RANTES can enhance its role in chemotaxis. By increasing the local concentration of RANTES, the district can attract the cells by the concentration gradient of the cytokine.

This study successfully constructed a selective replication adenovirus SG511-CCL5-ODD, in which the hTERT promoter drives the E1a gene and the hypoxia response promoter controls the E1b gene. This adenovirus is specifically replicated in tumor cells. ELISA assay was used to detect RANTES protein expression in tumor cells infected with SG511-CCL5-ODD. We found RANTES protein expression was different in both normoxic and hypoxic conditions, when in the same MOI and at the same time. Expression in hypoxia was significantly higher than in normoxia (P<0.05), confirming that adenovirus SG511-CCL5-ODD in hypoxic conditions has a stronger ability of gene expression. The results proved the RANTES gene under the control of ODD, RANTES protein in normal oxygen conditions is partially degraded.

The chemotaxis test is a method used to test the effectiveness of chemokine. Compared with the control, we found the virus in liver cancer cells could highly express RANTES protein and had a strong chemotactic effect to NK-92 cells. The supernatant of liver cancer cells which was infected by SG511-CCL5-ODD was more effective to chemotaxis NK-92 cells in hypoxic conditions. The RANTES protein was confirmed as a strong chemotaxis agent for NK-92 cells. High concentrations of local tumor chemokine RANTES protein attract immune cells around the tumor tissue to maintain a high concentration of immune cells, which is key to cancer biological therapy.

In the liver cancer xenograft model, significant tumor growth inhibition was demonstrated in all the treatment groups compared with the control group. From day 14 after treatment,
Figure 4. Antitumor efficacy of RANTES in SMMC-7721 tumor xenografts. Mice were given five intratumoral injections to introduce viruses into SMMC-7721 xenografts, one injection every other day with 2x10^8 plaque-forming units/dose/mouse. The potent antitumor effect was shown in all virus-treated groups. SG511-CCL5-ODD showed the best antitumor growth effect. The antitumor effect of SG511-CCL5-ODD and AD5/11-CCL5-ODD was stronger than that of SG511. (A-D) Pathological examination of tumor specimens, magnification x200. H&E staining showed wide areas of necrosis in tumor tissues of the SG511-CCL5-ODD-treated group, but cancer cells grew abundantly in the control group; (A) control; (B) SG511; (C) AD5/11-CCL5-ODD; (D) SG511-CCL5-ODD.

Figure 5. Antitumor efficacy of RANTES combined with NK92 in SMMC-7721 tumor xenografts. (A) Mice were given five intratumoral injections to introduce SG511-CCL5-ODD viruses into SMMC-7721 xenografts, one injection every other day with 2x10^8 plaque-forming units/dose/mouse or given five intravenous inoculations of 5x10^6 NK-92 cells five times, once every other day. The potent antitumor effect was shown in all virus-treated and/or NK92-treated groups. The combined group of SG511-CCL5-ODD and NK92 showed the best antitumor growth effect. The antitumor effect of NK92 was stronger than that of SG511-CCL5-ODD. (B) H&E staining pathological examination of tumor specimens, magnification x200. H&E staining showed wide areas of necrosis in tumor tissues of the SG511-CCL5-ODD combined with the NK92-treated group, but cancer cells grew abundantly in the control group. (C) The hepatocytes were positive for RANTES protein in mice of the NK92+SG511-CCL5-ODD and the SG511-CCL5-ODD group injected with SG511-CCL5-ODD; magnification x200.
the tumor volume in the mice treated with SG511-CCL5-ODD combined with NK-92 was suppressed more than that in the mice with any other treatment. After a 4-week treatment, when compared with the control group, the tumor volume was reduced by 68.54% and 53.19%, respectively, in Group III (SG511-CCL5-ODD+NK-92) and Group II (NK-92), and Group III (SG511-CCL5-ODD+NK-92) showed more tumor repression than Group II (NK-92) (P<0.01). These results indicate that all treatments [including I (SG511-CCL5-ODD), II (NK-92) and III (SG511-CCL5-ODD+NK-92)] inhibited tumor growth and III (SG511-CCL5-ODD+NK-92) is the most efficient agent among them. Therefore, immune cell-viral therapy is superior to simple immunotherapy and virotherapy.

Acknowledgements

This study was financially supported by the Key Program of the National Natural Science Foundation of China (No. 81071850) and the National Science Funds for Distinguished Young Scholars (No. 30925037).

References

1. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich JR, Restifo NP, Thomasian A, Downey SG, Smith FO, Klinger JO, Morton K, Laurencoct C, White DE and Rosenberg SA: Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26: 5233-5239, 2008.

2. Dudley ME, Wunderlich JR, Shelton TE, Even J and Rosenberg SA: Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26: 332-343, 2003.

3. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal R, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A and Rosenberg SA: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 46-56, 2005.

4. Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L, Yu Z, Rosenberg SA and Restifo NP: Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother 33: 3-12, 2010.

5. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan QG, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencoct CM, Steinberg SM, White DE and Dudley ME: Durable complete responses in heavily pretreated patients with metastatic melanoma using UCB T cell transfer immunotherapy. Clin Cancer Res 17: 4550-4557, 2011.

6. Ripley RT, Davis JL, Klapper JA, Mathur A, Kammula U, Royal RE, Yang JC, Sherry RM, Hughes MS, Libutti SK, White DE, Steinberg SM, Dudley ME, Rosenberg SA and Avital I: Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy. Ann Surg Oncol 17: 163-170, 2010.

7. Rosenberg SA and Dudley ME: Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21: 233-240, 2009.

8. Pittet MJ and Mempel TR: Regulation of T-cell migration and receptor functions: insights from in vivo imaging studies. Immunol Rev 221: 107-129, 2008.

9. Braun SE, Chen K, Foster RG, Kim CH, Hromas R, Kaplan MH, Broxmeyer HE and Cornetta K: The cc chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J Immunol 164: 4025-4031, 2000.

10. Hromas R, Cripe L, Hangoc G, Cooper S and Broxmeyer HE: The exodus subfamily of CC chemokines inhibits the proliferation of chronic myelogenous leukemia progenitors. Blood 95: 1506-1508, 2000.

11. Sharma S, Stolina M, Luo J, Strietier RM, Burdick M, Zhu LX, Batra KK and Dubinett SM: Secondary lymphoid tissue chemokine mediates T-cell dependent antitumor responses in vivo. J Immunol 175: 4558-4563, 2005.

12. Kudo T, Lu H, Wu JY, Graham DY, Casola A and Yamazaki Y: Regulation of RANTES promoter activation in gastric epithelial cells infected with Helicobacter pylori. Infect Immun 73: 7602-7612, 2005.

13. Lebovic DI, Chao VA and Taylor RN: Peritoneal macrophages induce RANTES (regulated on activation, normal T cell expressed and secreted) chemokine gene transcription in endometrial stromal cells. J Clin Endocrinol Metab 89: 1397-1401, 2004.

14. Veillard NR, Kwak B, Pelli G, Mulhaupt F, James RW, Proudfoot AE and Mach F: Antagonism of RANTES receptors reduces atheromatous plaque formation in mice. Circ Res 94: 253-261, 2004.

15. Rojas-Ramos E, Avalos AF, Perez-Fernandez L, Cuevas-Schacht F, Valencia-Maqueeda E and Teran LM: Role of the chemokines RANTES, monocyte chemotactic proteins-3 and -4 and eotaxins-1 and -2 in childhood asthma. Eur Respir J 22: 310-316, 2003.

16. Chen CJ, Chen JH, Chen SY, Liao SL and Raung SL: Upregulation of RANTES gene expression in neuroglia by Japanese encephalitis virus infection. J Virol 78: 12107-12119, 2004.

17. Ottmanns U, Issa R, Sukkar MB, John M and Chung KF: Role of c-jun N-terminal kinase in the induced release of GM-CSF, RANTES and IL-8 from human airway smooth muscle cells. Br J Pharmacol 139: 1228-1234, 2003.

18. Teichmann JV, Ludwig WD and Thiel E: Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferon and tumor necrosis factor. Leuk Res 16: 287-298, 1992.

19. Pauwels C: MHCI-unrestricted immune surveillance of leukemia. Cancer Biother 9: 265-288, 1994.

20. Dokhelar MC, Wiels J, Lipinski M, Tetaud C, Devergie A, Gluckman E and Turz T: Natural killer cell activity in human bone marrow recipients: early reappearance of peripheral natural killer cell activity in graft-versus-host disease. Transplantation 31: 61-65, 1981.

21. Cerwenka A and Lanier RL: Natural killer cells, viruses and cancer. Nat Rev Immunol 1: 41-49, 2001.

22. Lanier RL: NK cell recognition. Annu Rev Immunol 23: 225-274, 2005.

23. Drexler HG and Matsuo Y: Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma. Leukemia 14: 777-782, 2000.

24. Yan Y, Steinhzer P, Klingemann HG, Dennig D, Childs BH, McGuirk J and O'Reilly RJ: Antileukemia activity of a natural killer cell line against human leukemias. Clin Cancer Res 4: 75-86, 1998.

25. Gong JH, Maki G and Klingemann HG: Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8: 652-658, 1994.

26. Reed GS, Bharya S, Klingemann HG and Schultz KR: Differential killing of pre-B acute lymphoblastic leukaemia cells by activated NK cells and the NK-92 ci cell line. Clin Exp Immunol 129: 265-271, 2002.

27. Tam YK, Miyagawa B, Ho VC and Klingemann HG: Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J Hematother 8: 281-290, 1999.

28. Toni T, Becker S, Esser R, Schwabe D and Seifried E: Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 10: 535-544, 2001.

29. Bergsagelson JM, Cunningham JA, Drogett G, Kurt-Jones EA, Thrivais A, Hong JS, Horwitz MS, Crowell RL and Finberg RW: Isoform and secreted) chemokine gene transcription in endometrial stromal cells. J Immunol 164: 4025-4031, 2000.

30. Hromas R, Cripe L, Hangoc G, Cooper S and Broxmeyer HE: The exodus subfamily of CC chemokines inhibits the proliferation of chronic myelogenous leukemia progenitors. Blood 95: 1506-1508, 2000.
33. Yamamoto H, Itoh F, Sakamoto H, Nakajima Y, Une Y, Hinoda Y and Imai K: Association of reduced cell adhesion regulator messenger RNA expression with tumor progression in human hepatocellular carcinoma. Int J Cancer 74: 251-254, 1997.
34. Gaggar A, Shayakhmetov DM and Lieber A: CD46 is a cellular receptor for group B adenoviruses. Nat Med 9: 1408-1412, 2003.
35. Hara T, Kojima A, Fukuda H, Masaoka T, Fukumori Y, Matsumoto M and Seya T: Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human hematological malignancies. Br J Haematol 82: 368-373, 1992.
36. Kinugasa N, Higashi, T, Nousu K, Nakatsukasa H, Kobayashi Y, Ishizaki M, Toshikuni N, Yoshida K, Uematsu S and Tsuji T: Expression of membrane cofactor protein (MCP, CD46) in human liver diseases. Br J Cancer 80: 1820-1825, 1999.
37. Murray KP, Mathure S, Kaul R, Khan S, Carson LF, Twigg LS, Martens MG and Kaul A: Expression of complement regulatory proteins-CD 35, CD 46, CD 55 and CD 59-in benign and malignant endometrial tissue. Gynecol Oncol 76: 176-182, 2000.
38. Thorsteinsson L, O’ Dowd GM, Harrington GM and Johnson PM: The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues. APMIS 106: 869-878, 1998.
39. Vähä-Koskela MJ, Heikkilä JE and Hinkkanen AE: Oncolytic viruses in cancer therapy. Cancer Lett 254: 178-186, 2007.
40. Liu X, Qian Q, Xu P, Wolf F, Zhang J, Zhang D, Li C and Huang Q: A novel conditionally replicating ‘armed’ adenovirus selectively targeting gastrointestinal tumors with aberrant Wnt signaling. Hum Gene Ther 22: 427-437, 2011.
41. Xie M, Niu JH, Chang Y, Qian QJ, Wu HP, Li LF, Zhang Y, Li JL, Huang XJ and Ruan GR: A novel triple-regulated oncolytic adenovirus carrying PDCD5 gene exerts potent antitumor efficacy on common human leukemic cell lines. Apoptosis 14: 1086-1094, 2009.
42. Harada H, Hiraoka M and Kizaka-Kondoh S: Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res 62: 2013-2018, 2002.
43. Teicher BA: Hypoxia and drug resistance. Cancer Metastasis Rev 13: 139-168, 1994.
44. Kung AL, Wang S, Kico JM, Kaclin WG and Livingston DM: Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 6: 1335-1340, 2000.
45. Helmlinger G, Yuan F, Dellian M and Jain RK: Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 3: 177-182, 1997.
46. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Baechler P, Isaacs WB, Semenza GL and Simons JW: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835, 1999.
47. Zhang Q, Chen G, Peng L, Wang X, Yang Y, Liu C, Shi W, Su C, Wu H, Liu X, Wu M and Qian Q: Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus. Clin Cancer Res 12: 6523-6531, 2006.